Oppenheimer & Co. Inc. Acquires 5,688 Shares of AbbVie Inc. $ABBV

Oppenheimer & Co. Inc. lifted its holdings in AbbVie Inc. (NYSE:ABBV) by 3.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 167,541 shares of the company’s stock after purchasing an additional 5,688 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in AbbVie were worth $38,792,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of ABBV. Diversified Trust Co lifted its stake in AbbVie by 23.6% in the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after purchasing an additional 10,891 shares during the last quarter. Permanent Capital Management LP acquired a new position in shares of AbbVie during the third quarter worth $720,000. Railway Pension Investments Ltd lifted its stake in shares of AbbVie by 33.0% in the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after acquiring an additional 211,800 shares during the last quarter. World Investment Advisors boosted its holdings in shares of AbbVie by 9.4% during the 3rd quarter. World Investment Advisors now owns 113,925 shares of the company’s stock valued at $26,378,000 after acquiring an additional 9,811 shares in the last quarter. Finally, Charles Schwab Trust Co grew its position in AbbVie by 93.4% during the 3rd quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock worth $7,434,000 after acquiring an additional 15,502 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ABBV shares. Piper Sandler reiterated an “overweight” rating and issued a $289.00 target price (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Erste Group Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Morgan Stanley upped their price target on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and raised their price target for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $251.00.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Morgan Stanley raised its price target to $270 and kept an “overweight” call, signaling institutional analyst conviction that AbbVie has double‑digit upside from current levels. Read More.
• Positive Sentiment: Company forecasts for full‑year 2026 profit came in above estimates, driven by strong sales of newer immunology drugs (Skyrizi, Rinvoq), supporting the case for continued top‑line and earnings growth. Read More.
• Positive Sentiment: Market commentary and some analysts view the post‑earnings pullback as a buying opportunity, pointing to institutional accumulation, durable cash flow, and a strong dividend as anchors for medium‑term returns. Read More.
• Positive Sentiment: New real‑world Rinvoq data from Japan bolsters the drug’s addressable market for ankylosing spondylitis and reinforces growth prospects for AbbVie’s immunology franchise. Read More.
• Neutral Sentiment: Management framed the earnings call around “new growth engines” — Skyrizi/Rinvoq and other launches taking the lead in driving growth, which supports the long‑term story but doesn’t eliminate near‑term volatility. Read More.
• Neutral Sentiment: Q4 results beat on revenue and showed strong margin/earnings leverage, confirming product momentum even as some segments face headwinds. Read More.
• Negative Sentiment: Shares initially gapped down after the print as investors focused on a softer-than‑expected Q1 EPS and revenue outlook despite the quarter’s beats — a classic near‑term reaction to guidance misses. Read More.
• Negative Sentiment: AbbVie set Q1 2026 EPS guidance at $2.97–$3.01 (vs. ~3.11 consensus) and gave revenue guidance below the street, creating short‑term uncertainty about the cadence of 2026 growth. Read More.
• Negative Sentiment: Broader coverage highlighted investor “angst” and a bifurcated reaction — bullish on medium‑term fundamentals but worried about near‑term comps and valuation — keeping volatility elevated. Read More.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $223.50 on Monday. The company’s 50 day moving average price is $223.74 and its 200-day moving average price is $219.84. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The company has a market capitalization of $395.01 billion, a P/E ratio of 94.70, a price-to-earnings-growth ratio of 0.85 and a beta of 0.35.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.